lncRNA PCAT14 Is a Diagnostic Marker for Prostate Cancer and Is Associated with Immune Cell Infiltration

Table 2

Cox univariable and multivariable analysis of PFI in prostate cancer patients.

	Total ()	Univariable analysis		Multivariable analysis
		Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
T stage (T3&T4 vs. T2)	492	3.785 (2.140-6.693)	<0.001	1.473 (0.710-3.059)	0.299
N stage (N1 vs. N0)	426	1.946 (1.202-3.150)	0.007	0.861 (0.500-1.483)	0.589
M stage (M1 vs. M0)	458	3.566 (0.494-25.753)	0.208
Primary therapy outcome (PD&SD&PR vs. CR)	438	6.627 (4.337-10.126)	<0.001	3.576 (2.054-6.226)	<0.001
Race (Asian & Black or African American vs. White)	484	0.751 (0.417-1.352)	0.339
Age (>60 vs. ≤60)	499	1.302 (0.863-1.963)	0.208
Residual tumor (R1&R2 vs. R0)	468	2.365 (1.566-3.570)	<0.001	1.017 (0.598-1.728)	0.951
PSA (ng/ml) (≥4 vs. <4)	442	4.196 (2.095-8.405)	<0.001	1.650 (0.743-3.667)	0.219
Gleason score (8-10 vs. 6-7)	499	4.675 (2.957-7.391)	<0.001	2.901 (1.603-5.253)	<0.001

CI: confidence interval; PSA: prostate-specific antigen.